학술논문
MicroRNAs associated with postoperative outcomes in patients with limited stage neuroendocrine carcinoma of the esophagus
Document Type
Academic Journal
Author
Okumura, Tomoyuki; Fujii, Tsutomu; Terabayashi, Kenji; Kojima, Takashi; Takeda, Shigeru; Kashiwada, Tomomi; Toriyama, Kazuhiro; Hijioka, Susumu; Miyazaki, Tatsuya; Yamamoto, Miho; Tanabe, Shunsuke; Shirakawa, Yasuhiro; Furukawa, Masayuki; Honma, Yoshitaka; Hoshino, Isamu; Nabeya, Yoshihiro; Yamaguchi, Hironori; Uemoto, Shinji; Shimada, Yutaka; Matsubara, Hisahiro; Ozawa, Soji; Makuuchi, Hiroyasu; Imamura, Masayuki
Source
Oncology Letters. July, 2023, Vol. 26 Issue 1, p1a, p18 p.
Subject
Language
English
ISSN
1792-1074
Abstract
Esophageal neuroendocrine carcinoma (E-NEC) is an aggressive disease with a poor prognosis. The present study aimed to assess the role of surgery in the treatment of patients with resectable E-NEC, and identify a microRNA (miRNA/miR) signature in association with positive postoperative outcomes. Between February 2017 and August 2019, 36 patients with E-NEC who underwent curative surgery at the Japan Neuroendocrine Tumor Society partner hospitals were enrolled in the study. A total of 16 (44.4%) patients achieved disease-free survival (non-relapse group), whereas 20 (55.6%) patients developed tumor relapse (relapse group) during the median follow-up time of 36.5 months (range, 1-242) after surgery with a 5-year overall survival rate of 100 and 10.8%, respectively (P
Introduction Neuroendocrine carcinoma (NEC) of the esophagus (E-NEC) is rare, accounting for ~1% of all esophageal malignancies (1,2). NEC is defined as a poorly differentiated carcinoma with neuroendocrine differentiation and [...]
Introduction Neuroendocrine carcinoma (NEC) of the esophagus (E-NEC) is rare, accounting for ~1% of all esophageal malignancies (1,2). NEC is defined as a poorly differentiated carcinoma with neuroendocrine differentiation and [...]